A Phase 1 interventional study of Gemigliptin and Irbesartan in Healthy, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-30.
Sponsored by LG Life Sciences (part of LG Chem) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to investigate the drug interaction between Gemigliptin and Irbesartan by comparing pharmacokinetics of Gemigliptin and Irbesartan administered concomitantly and each alone in healthy male subjects.
LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
First submitted before LG Life Sciences became part of LG Chem.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 20 to 45, healthy male subjects (at screening)
Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemigliptin 50mg q.d. during 7 days
Drug: Gemigliptin
Irbesartan 300mg q.d. during 7 days
Drug: Irbesartan
Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
Drug: Gemigliptin · Drug: Irbesartan
Cmax,ss
To evaluate Cmax,ss of Gemigliptin and Irbesartan
Time frame: up to 72h post-dose
AUCτ,ss
To evaluate AUCτ,ss of Gemigliptin and Irbesartan
Time frame: up to 72h post-dose
Cmin,ss
To evaluate Cmin,ss of Gemigliptin and Irbesartan
Time frame: up to 72h post-dose
Tmax,ss
To evaluate Tmax,ss of Gemigliptin, Irbesartan and LC15-0636 (active metaboilite of Gemigliptin)
Time frame: up to 72h post-dose
Cmax,ss
To evaluate Cmax,ss of LC15-0636 (active metaboilite of Gemigliptin)
Time frame: up to 72h post-dose
AUCτ,ss
To evaluate AUCτ,ss of LC15-0636(active metabolite of Gemigliptin)
Time frame: up to 72h post-dose
metabolic ratio
To evaluate metabolic ratio of LC15-0636(active metabolite of Gemigliptin)
Time frame: up to 72h post-dose
The record gives a start of Jun 2013, a primary completion of Sep 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemigliptin · Irbesartan